Improved psychological status of children under DDAVP therapy for central diabetes insipidus

Rw, Waggoner; Ae, Slonim; Sh, Armstrong

doi:10.1176/ajp.135.3.361

Cited by 12 publications

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vasopressin and Human Behavior

Jolles

1987

Vasopressin

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Vasopressin and Human Behavior

Jolles

1987

Vasopressin

View full text Add to dashboard Cite

show abstract

Vasopressin in Neuropsychiatric Disorders

Legros

Lancranjan²

1984

Psychoneuroendocrine Dysfunction

View full text Add to dashboard Cite

Does DGAVP influence memory, attention and mood in young healthy men?

1987

View full text Add to dashboard Cite

The influence of an increasing dose of the vasopressin-like peptide DGAVP (desglycinamide-arginine-vasopressin) on memory was investigated in two groups of ten healthy male volunteers to provide information about the hypothesis of improvement of memory by vasopressin. At the same time we evaluated the effect of DGAVP on mood, alertness or sleepiness in a double-blind placebo-control design. The treatment group received at 9.15 a.m. intranasally a daily increasing dose from 0.1 mg at day 1 to 10.0 mg at day 5. DGAVP did not significantly affect any measure of memory or alertness. DGAVP did, however, produce a significant increase in concentration level and mood. The results of the present study provide no support for the vasopressin theory of memory improvement; rather, the results direct the attention to attention modulating effects.

show abstract

Improved psychological status of children under DDAVP therapy for central diabetes insipidus

Cited by 12 publications

References 2 publications

Vasopressin and Human Behavior

Vasopressin and Human Behavior

Vasopressin in Neuropsychiatric Disorders

Does DGAVP influence memory, attention and mood in young healthy men?

Contact Info

Product

Resources

About